<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170116</url>
  </required_header>
  <id_info>
    <org_study_id>1160.1</org_study_id>
    <nct_id>NCT02170116</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers</brief_title>
  <official_title>Pharmacodynamics, Safety and Pharmacokinetics After Single Oral Administration of 10, 30, 100, 200 and 400 mg BIBR 1048 MS as Drinking Solution in Healthy Subjects. An Open Study, Placebo Randomized Double Blind at Each Dose Level.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study was to assess safety, pharmacokinetics and the effect of BIBR 953&#xD;
      ZW on coagulation parameters of BIBR 953 ZW after oral single doses of the prodrug, BIBR 1048&#xD;
      MS, in healthy male subjects. This was the first administration of this substance to humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <primary_completion_date type="Actual">December 1998</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in prothrombin time (PT) (International Normalised Ratio (INR))</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in activated partial thromboplastin time (aPTT)</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak (maximum) plasma concentration (Cmax) of BIBR 953 ZW</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach the peak plasma concentration (tmax ) of BIBR 953 ZW</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-12 h - Area under the plasma concentration-time curve of BIBR 953 ZW from 0 to 12 h</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC0-infinity) of BIBR 953 ZW from 0 to infinity</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve of BIBR 953 ZW (AUCtf -infinity) from tf (last time point when measured plasma concentration) to infinity expressed as % of AUC0-infinity</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life(t1/2 ) of BIBR 953 ZW derived from non-compartmental analysis</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mean residence time (MRTtot ) of BIBR 953 ZW</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance (CLtot /f ) of BIBR 953 ZW after oral administration</measure>
    <time_frame>24 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz/f ) of BIBR 953 ZW during terminal phase after oral administration</measure>
    <time_frame>- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Pulse rate</measure>
    <time_frame>up to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Systolic and diastolic blood pressure</measure>
    <time_frame>up to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse events</measure>
    <time_frame>up to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Ecarin Clotting Time (ECT)</measure>
    <time_frame>up to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in thrombin inhibition test time</measure>
    <time_frame>up to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in thrombin time</measure>
    <time_frame>up to day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBR 1048 MS dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 MS dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 MS dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 MS dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 MS dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS dose 1</intervention_name>
    <arm_group_label>BIBR 1048 MS dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS dose 2</intervention_name>
    <arm_group_label>BIBR 1048 MS dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS dose 3</intervention_name>
    <arm_group_label>BIBR 1048 MS dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS dose 4</intervention_name>
    <arm_group_label>BIBR 1048 MS dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS dose 5</intervention_name>
    <arm_group_label>BIBR 1048 MS dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BIBR 1048 MS</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects as determined by results of screening&#xD;
&#xD;
          -  Signed written informed consent in accordance with Good Clinical Practice (GCP) and&#xD;
             local legislation&#xD;
&#xD;
          -  Age &gt;= 18 and &lt;= 45 years&#xD;
&#xD;
          -  Broca &gt;= - 20 % and &lt;= + 20 %&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of the medical examination (including blood pressure, pulse rate and ECG)&#xD;
             deviating from normal and of clinical relevance&#xD;
&#xD;
          -  History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,&#xD;
             metabolic, immunologic, hormonal disorders&#xD;
&#xD;
          -  History of orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of&#xD;
&#xD;
               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the&#xD;
                  trial as judged by the investigator&#xD;
&#xD;
               -  any bleeding disorder including prolonged or habitual bleeding&#xD;
&#xD;
               -  other hematologic disease&#xD;
&#xD;
               -  cerebral bleeding (e.g. after a car accident)&#xD;
&#xD;
               -  commotion cerebri&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt; 24 hours) within 1 month prior to&#xD;
             administration&#xD;
&#xD;
          -  Use of any drugs which might influence the results of the trial within 10 days prior&#xD;
             to administration or during the trial&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within 2 months prior to&#xD;
             administration or during trial&#xD;
&#xD;
          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from&#xD;
             smoking on study days&#xD;
&#xD;
          -  Alcohol abuse (&gt; 60 g/day)&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Blood donation within 1 month prior to administration or during the trial&#xD;
&#xD;
          -  Excessive physical activities within 5 days prior to administration or during the&#xD;
             trial&#xD;
&#xD;
          -  Any laboratory value outside the clinically accepted reference range&#xD;
&#xD;
          -  History of any familial bleeding disorder&#xD;
&#xD;
          -  Thrombocytes &lt; 150000/Âµl&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1160/1160.1_U99-1502.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

